Medical Advocates
HAART/ART
 
Economics

Internet Documents
 Journal Citations
 Conference Citations





 

 


 
HAART Main Page Main New/Newsworthy   Home Page    
Last Update:  June 16, 2008  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Internet Documents
     
  A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 The Very Model of a Modern Major Modeler: An Interview with Kit N. Simpson, DrPH
on her New Cost-of Care Model for HIV Care
Simpson KN, Hawes J  
January 16, 2008
 Interview
Journal Papers, Abstracts, and Commentaries
     
 
A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy.
Hornberger J, Holodniy M, Robertus K, et al
Med Decis Making. 2007 Nov-Dec;27(6):789-821.
 Abstract
 
Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in
Thailand. 
Tantivess S, Walt G.
Cost Eff Resour Alloc. 2006 Dec 30;4(1):21|
 Abstract
 
Costs versus benefits: best possible and best practical treatment regimens for HIV.
Krakovska O, Wahl LM.
 J Math Biol. 2007 Jan 5
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Comparing costs and effectiveness of different starting points for highly active antiretroviral
therapy in HIV-positive patients Evidence from the ICONA cohort.
Merito M, Pezzotti P; for the ICONA Study Group.
Eur J Health Econ. 2006 Jan 11;
 Abstract

Costs associated with combination antiretroviral therapy in HIV-infected
patients.
Yazdanpanah Y.
J Antimicrob Chemother. 2004 Feb 25
 Abstract
Conference Reports, Abstracts, and Posters
     
  PDF POSTER
 Comparing the cost-effectiveness of first-line HAART regimens
 D Bishai,  S Haberlen,  L Spacek, MD,  et al 
(11th European AIDS Conference)
 Poster
 
PDF POSTER
 Comparison of Markov and Discrete Event Simulation Models to Predict Economic
Outcomes for ARV Therapies in HIV Disease
 KN Simpson, A. Strasburger III, B. Dietz, et al
(11th European AIDS Conference)
Poster
 
Economic and clinical impact of using a protease inhibitor regimen containing atazanavir +
ritonavir vs. lopinavir/ritonavir in antiretroviral (ARV) experienced patients: modeling the
lifetime impacts of the 48 week results from BMS AI424-045
 KN Simpson, GE MacKinnin III,
(11th European AIDS Conference
 Abstract
 
Predicted future effects of level of Viral Load (VL) suppression by the 36th week
Simpson K.N., Rajagopalan R., Dietz B
 (Eighth International Congress on Drug Therapy and HIV Infection
 Abstract
 
Cost effectiveness of lopinavir/r tablets compared to atazanavir + ritonavir in antiretroviral
experienced patients in the UK, Spain, Italy, and France based on results from BMS
AI424-045
 Simpson K.N, Jones W., Rajagopalan R., Dietz B.
 (Eighth International Congress on Drug Therapy and HIV Infection
 Abstract
 
PDF POSTER
 Comparison of Markov and Discrete Event Simulation Models for HIV-Disease
 KN Simpson, A. Strasburger III. W Jones, et al
 [47 ICAAC]
Poster
 
PDF POSTER
Economic and Clinical Impact of Using a Protease Inhibitor Regimen Containing
ATV + RTV vs. Lopinavir/Ritonavir in Antiretroviral (ARV) Experienced Patients:
Modeling the Lifetime Impacts of the 48-Week Results from BMS AI424-045
KN. Simpson, G MacKinnon
 [47 ICAAC]
Poster



 
HAART Main Page Main New/Newsworthy   Home Page    

HAART/ARVs Economics